Karolyn A Oetjen Selected Research

Therapeutic Uses

1/2022

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karolyn A Oetjen Research Topics

Disease

3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2017
3	Leukemia 01/2022 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2017
2	Neoplasms (Cancer) 01/2017 - 02/2009
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2022
1	Primary Myelofibrosis (Myelosclerosis) 01/2022
1	Trichothiodystrophy Syndromes 01/2019
1	Neutropenia 01/2017
1	Infections 01/2017
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 04/2009
1	Necrosis 04/2009

Drug/Important Bio-Agent (IBA)

1	RNA (Ribonucleic Acid)IBA 10/2022
1	pembrolizumabIBA 01/2022
1	Decitabine FDA Link 01/2022
1	Therapeutic UsesIBA 01/2022
1	JNK Mitogen-Activated Protein KinasesIBA 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	LigandsIBA 01/2019
1	AntigensIBA 01/2017
1	Immune Checkpoint InhibitorsIBA 01/2017
1	TNF Receptor-Associated Factor 2 (TRAF2)IBA 04/2009

Therapy/Procedure

3	Therapeutics 01/2022 - 02/2009
1	Cell Transplantation 01/2022
1	Precision Medicine 01/2021
1	Homologous Transplantation 01/2017
1	Consolidation Chemotherapy 01/2017
1	Hematopoietic Stem Cell Transplantation 01/2017
1	Drug Therapy (Chemotherapy) 01/2017
1	Induction Chemotherapy 01/2017